Cantor Fitzgerald reaffirmed their overweight rating on shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) in a research note published on Tuesday. Cantor Fitzgerald also issued estimates for GW Pharmaceuticals PLC-‘s FY2019 earnings at ($6.24) EPS.
GWPH has been the subject of a number of other research reports. Zacks Investment Research upgraded GW Pharmaceuticals PLC- from a hold rating to a strong-buy rating and set a $168.00 price objective for the company in a research report on Wednesday, October 10th. BidaskClub upgraded GW Pharmaceuticals PLC- from a hold rating to a buy rating in a research report on Saturday, September 22nd. Piper Jaffray Companies reiterated an overweight rating on shares of GW Pharmaceuticals PLC- in a research report on Monday, November 5th. Bank of America reiterated a buy rating and set a $197.00 price objective (up previously from $181.00) on shares of GW Pharmaceuticals PLC- in a research report on Friday, September 28th. Finally, Morgan Stanley set a $227.00 price objective on GW Pharmaceuticals PLC- and gave the stock a buy rating in a research report on Thursday, October 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $185.38.
GW Pharmaceuticals PLC- stock opened at $124.84 on Tuesday. GW Pharmaceuticals PLC- has a 52 week low of $105.12 and a 52 week high of $179.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.66 and a quick ratio of 6.34.
Large investors have recently modified their holdings of the business. Flagship Harbor Advisors LLC acquired a new stake in GW Pharmaceuticals PLC- in the 2nd quarter worth about $109,000. Envestnet Asset Management Inc. acquired a new stake in GW Pharmaceuticals PLC- in the 2nd quarter worth about $119,000. Cowen Prime Services LLC boosted its stake in GW Pharmaceuticals PLC- by 708.0% in the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 885 shares during the last quarter. NumerixS Investment Technologies Inc acquired a new stake in GW Pharmaceuticals PLC- in the 2nd quarter worth about $166,000. Finally, BNP Paribas Arbitrage SA boosted its stake in GW Pharmaceuticals PLC- by 497.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock worth $167,000 after buying an additional 999 shares during the last quarter. 69.38% of the stock is currently owned by hedge funds and other institutional investors.
About GW Pharmaceuticals PLC-
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.